You seem to be using a wider screen, would you like to enable a wider viewing experience on this page?
Herantis Pharma: Disease-modifying drug for Parkinson’s
We have initiated coverage of Herantis Pharma, a drug development company focused on neurodegenerative diseases. In this interview analyst Antti Siltanen sheds light on what the company does, what its drug candidate HER-096 is all about, competing drug candidates and other pressing questions regarding the company.
Content:
00:00 Intro
00:16 What does Herantis do?
00:52 How does HER-096 work?
01:20 Risks
03:19 Competing drug candidates
04:57 Capital adequacy and funding options
06:23 Probability of commercialization
07:12 When to expect profit generation?
Mød og stil spørgsmål til koncernchef Michael Rasmussen om Nykredits købstilbud på Spar Nord
Tokmanni's analyst and press event at 2:00 pm EET
Gabriel FY'2023/24 video – Waiting for the carve-out to unlock value
Aktier med Friis - Uge 2 2025
LeadDesk: Transformation into a cash flow machine
Vis alle videoer